SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
Active, not recruiting
AstraZeneca
Phase 2
Open label multicentric randomized phase II trial, using high throughput genome analysis as a
therapeutic decision tool, aimed at comparing a targeted treatment administered according to
the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in
Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as
immunotherapy with maintenance therapy in patients without actionable genomic alterations or
non eligible to substudy 1 (immune substudy 2).
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
Active, not recruiting
Fondation ARC
Phase 2
Open label multicentric randomized phase II trial, using high throughput genome analysis as a
therapeutic decision tool, aimed at comparing a targeted treatment administered according to
the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in
Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as
immunotherapy with maintenance therapy in patients without actionable genomic alterations or
non eligible to substudy 1 (immune substudy 2).
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
Active, not recruiting
IFCT
Phase 2
Open label multicentric randomized phase II trial, using high throughput genome analysis as a
therapeutic decision tool, aimed at comparing a targeted treatment administered according to
the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in
Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as
immunotherapy with maintenance therapy in patients without actionable genomic alterations or
non eligible to substudy 1 (immune substudy 2).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
